ArticleJAMA ophthalmology2017
An Outbreak of Endogenous Fungal Endophthalmitis Among Intravenous Drug Abusers in New England.
Article in JAMA ophthalmology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 69 citations in OpenAlex.
- Aspergillus Endophthalmitis: Clinical Features, Treatment Modalities, and Visual Outcomes.Investigative ophthalmology & visual science · 2026Article
- An outbreak of endogenous fungal endophthalmitis in immunocompetent individuals caused by presumed intravenous infusion contamination.Frontiers in cellular and infection microbiology · 2026Article
- International consensuses and guidelines on diagnosing and managing fungal endophthalmitis by the Asia-Pacific Vitreo-retina Society (APVRS), the Academy of the Asia-Pacific Professors of Ophthalmology (AAPPO), and the Asia-Pacific Society of Ocular Inflammation and Infection (APSOII).Eye and vision (London, England) · 2025Review
- State-of-the-Art Review: Ocular Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Literature- and Experience-Based Consensus for Acute Post-operative Endophthalmitis and Endogenous Endophthalmitis in Taiwan.Ophthalmology and therapy · 2024Article
- Bilateral endogenousClinical case reports · 2023Article
- The Role of Adjuvant Systemic and Intravitreal Corticosteroids in Fungal Endophthalmitis Treatment.Journal of fungi (Basel, Switzerland) · 2023Review
- National emergency department trends for endogenous endophthalmitis: an increasing public health challenge.Eye (London, England) · 2023Article
- Molecular characterization of fungal endophthalmitis and keratitis caused by yeasts.Medical mycology · 2022Article
- The microbiological spectrum, antimicrobial resistance pattern, and visual outcomes of endogenous endophthalmitis in West Virginia 2009-2019.International ophthalmology · 2022Article
- Infection Sources andAntibiotics (Basel, Switzerland) · 2022Article
- Endogenous Fungal Endophthalmitis: Causative Organisms, Treatments, and Visual Outcomes.Journal of fungi (Basel, Switzerland) · 2022Article
- The Incidence of Ocular Complications in Candidemic Patients and Implications for the Practice of Routine Eye Exams.Open forum infectious diseases · 2022Article
- The Diagnosis and Treatment of Fungal Endophthalmitis: An Update.Diagnostics (Basel, Switzerland) · 2022Review
- Endogenous Endophthalmitis-The Clinical Significance of the Primary Source of Infection.Journal of clinical medicine · 2022Review
- Fungal Endophthalmitis: A Comprehensive Review.Journal of fungi (Basel, Switzerland) · 2021Review
- Sequential endogenous endophthalmitis, fungal keratitis, bacteremia and vertebral osteomyelitis in a person who injects drugs.American journal of ophthalmology case reports · 2021Article
- Practical Guidance for Clinical Microbiology Laboratories: Diagnosis of Ocular Infections.Clinical microbiology reviews · 2021Review
- Endogenous fungal endophthalmitis: risk factors, clinical course, and visual outcome in 13 patients.International journal of ophthalmology · 2021Article
- Culture-proven endogenous endophthalmitis: microbiological and clinical survey.International ophthalmology · 2020Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Intravenous drug abuse (IVDA) is a known risk factor for endogenous fungal endophthalmitis (EFE), a severe intraocular infection caused by hematogenous seeding of mycotic organisms to the eye. Reporting significant increases in heroin-related deaths since 2014, the New England region is in the midst of an opioid crisis that has led to a substantial increase in patients at risk for this vision-threatening disease. Objective: To present an update on characteristics, management, and visual outcomes in patients with EFE. Design, Setting, and Participants: Medical records review was initiated on July 1, 2016, evaluating all patients with EFE referred to New England Eye Center at Tufts Medical Center, a tertiary care ophthalmology practice distributed throughout Massachusetts, from May 1, 2014, to May 1, 2016. Patients with a history of IVDA and culture-proven or clinical evidence of fungal endophthalmitis were included. Exposures: Intravenous drug use. Main Outcomes and Measures: Patient demographics, comorbidities, presenting symptoms and vision, vitreoretinal findings, treatment regimens, culture data, and final visual acuities. Results: Ten patients (5 women) with IVDA-related EFE were identified between May 1, 2014, and May 1, 2016-an increase from 3 patients treated from May 2012 to April 2014. The mean (SD) patient age was 34 (11) years (range, 24-60 years). Presenting visual acuities ranged from 20/25 to hand motion. The most common presenting symptoms were floaters (n = 8), reduced vision (n = 6), and pain (n = 5). Initial treatment included systemic antifungals in all patients and intravitreal antifungals in 9 eyes. Five patients required pars plana vitrectomy for worsening vitritis. The most commonly isolated pathogen was Candida albicans in 20% of the patients. Final visual acuity ranged from 20/40 to 20/300. Conclusions and Relevance: The data provided in this report suggest that EFE represents severe end organ damage associated with IVDA and portends poor visual outcomes. Health care professionals must maintain a high suspicion for EFE, as patients are typically ambulatory on presentation without systemic signs of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.